Analyst Price Targets — REGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 12:54 pm | — | Morgan Stanley | $796.00 | $746.15 | TheFly | Regeneron price target raised to $796 from $769 at Morgan Stanley |
| April 8, 2026 10:49 am | — | Bernstein | $921.00 | $775.53 | TheFly | Regeneron price target lowered to $921 from $925 at Bernstein |
| March 9, 2026 1:41 pm | Greg Renza | Truist Financial | $818.00 | $770.32 | StreetInsider | Truist Securities Reiterates Buy Rating on Regeneron Pharma (REGN) following Ph3 study results |
| March 6, 2026 7:51 am | Eliana Merle | Barclays | $923.00 | $764.93 | StreetInsider | Barclays Starts Regeneron Pharma (REGN) at Overweight |
| March 2, 2026 1:46 pm | Brian Abrahams | RBC Capital | $765.00 | $784.06 | StreetInsider | Regeneron Pharma (REGN) PT Raised to $765 at RBC Capital |
| February 9, 2026 11:47 am | — | Guggenheim | $975.00 | $785.51 | TheFly | Regeneron price target raised to $975 from $865 at Guggenheim |
| February 2, 2026 1:02 pm | Carter Gould | Cantor Fitzgerald | $800.00 | $757.59 | TheFly | Regeneron price target raised to $800 from $740 at Cantor Fitzgerald |
| February 2, 2026 12:51 pm | Brian Skorney | Robert W. Baird | $742.00 | $755.34 | TheFly | Regeneron price target raised to $742 from $630 at Baird |
| February 2, 2026 12:32 pm | — | Oppenheimer | $865.00 | $741.45 | TheFly | Regeneron price target raised to $865 from $750 at Oppenheimer |
| February 2, 2026 12:01 pm | William Pickering | Tudor Pickering | $925.00 | $753.13 | StreetInsider | Regeneron Pharma (REGN) PT Raised to $925 at Bernstein SocGen Group |
Latest News for REGN
TARRYTOWN, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Lbp Am Sa decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 68.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,983 shares of the biopharmaceutical company's stock after selling 12,873 shares during the quarter. Lbp
Regeneron teams up with Telix in a 50/50 radiopharma deal, betting on next-gen cancer therapies to expand its oncology pipeline and long-term growth.
Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.